Farxiga Cost in Mississippi 2026: Cash Price, Medicaid, and Compounded Options

What Is the Actual Farxiga Cash Price in Mississippi Right Now?

The AstraZeneca list price for Farxiga is $620 per month for a 30-tablet supply of 10 mg tablets, and Mississippi retail pharmacies reflect that list price for uninsured, cash-paying patients. No major generic version of dapagliflozin is available in the United States as of mid-2025, so retail prices across Walgreens, CVS, Walmart, and independent Mississippi pharmacies hover within a few dollars of that figure.

GoodRx and similar coupon platforms can sometimes reduce that to the $500 to $580 range at specific Mississippi zip codes, but savings vary week to week and are not guaranteed. Patients should compare GoodRx, RxSaver, and the pharmacy's own discount program before filling.

Mississippi ranks among the states with the highest rates of type 2 diabetes. The CDC's 2022 Behavioral Risk Factor Surveillance System data placed Mississippi's adult diabetes prevalence at 15.6%, the second-highest in the nation. [1] That prevalence makes dapagliflozin access a meaningful public-health question in this state, not just a pricing footnote.

Dapagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. Beyond glycemic control, the FDA has approved it for reducing cardiovascular death or worsening heart failure in adults with heart failure regardless of ejection fraction, and for slowing CKD progression. [2] Those additional approvals mean the cost question matters to patients well beyond those with diabetes.

Does Mississippi Medicaid Cover Farxiga?

Mississippi Medicaid does not cover Farxiga as of 2026. The Mississippi Division of Medicaid (DOM) preferred drug list (PDL) does not include dapagliflozin on its covered formulary for Type 2 diabetes, heart failure, or CKD at this time. Providers can submit a prior authorization (PA) request, but approvals are rare without exceptional clinical documentation.

Mississippi DOM does cover metformin, sulfonylureas, and certain other diabetes medications on the standard PDL. For heart failure, formulary options tend to center on ACE inhibitors, beta-blockers, and aldosterone antagonists rather than SGLT2 inhibitors.

Patients enrolled in Mississippi Medicaid Managed Care Organizations (MCOs), including Magnolia Health and United Healthcare Community Plan of Mississippi, should check their specific plan's PDL independently, because MCO formularies can differ from the base DOM PDL. Calling the member services number on your insurance card is the fastest way to confirm current coverage.

The American Diabetes Association's 2024 Standards of Care in Diabetes explicitly recommends SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD. [3] The guideline states: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of a comprehensive cardiometabolic management plan." The gap between that guideline recommendation and Mississippi Medicaid's current formulary means many low-income Mississippi patients cannot access a drug their condition clinically warrants.

How the AstraZeneca Savings Card Works for Mississippi Patients

Commercially insured Mississippi patients who meet eligibility criteria can pay as little as $0 per month through AstraZeneca's Farxiga savings card program. The card applies to patients with private or employer-sponsored insurance, including marketplace plans. It does not apply to patients using Medicare, Medicaid, TRICARE, or other federal health programs.

To use the savings card, patients complete enrollment at AstraZeneca's patient-support site and present the card at any participating Mississippi pharmacy. The card covers the copay gap between what insurance pays and a $0 final patient cost, subject to an annual maximum benefit (currently $2,400 per year). Once the annual maximum is exhausted, the standard copay applies.

For uninsured or underinsured patients who do not qualify for the copay card, AstraZeneca operates the AZ&ME Prescription Savings program. Patients with household income at or below 600% of the federal poverty level may qualify to receive Farxiga at no cost through this program. Applications require income verification and a provider prescription. Processing typically takes two to four weeks.

Patients can apply at azandmepa.com or call 1-800-292-6363. Mississippi-based telehealth providers, including those operating through HealthRX, can submit the required documentation on a patient's behalf.

Is Compounded Dapagliflozin Legal in Mississippi?

Compounded dapagliflozin is legally permissible in Mississippi when prepared and dispensed by a state-licensed 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. Mississippi Board of Pharmacy regulations align with federal 503A standards.

A 503A pharmacy may legally compound dapagliflozin for a specific patient if a prescriber determines that the commercially available product does not meet that patient's clinical needs, for example because of a documented excipient allergy or a required dose form not commercially available. The prescription must be patient-specific, issued by a Mississippi-licensed prescriber or an out-of-state telehealth prescriber holding a valid Mississippi telemedicine registration.

One point of legal clarity worth stating directly: 503A compounders cannot produce copies of commercially available drugs without a documented clinical rationale. Simply citing cost is not, by itself, a recognized clinical rationale under current FDA enforcement guidance. [4] Prescribers who document a clinical reason can issue a valid 503A compound prescription, but cost-only rationale carries regulatory risk for both the pharmacy and the prescriber.

The practical cost outcome for a patient who qualifies can be significant. Compounded dapagliflozin formulations from 503A pharmacies typically cost between $0 and $80 per month depending on the pharmacy and formulation, compared with $620 for brand Farxiga.

503B outsourcing facilities operate under stricter FDA oversight and typically supply healthcare facilities rather than individual patients. No 503B facility currently has dapagliflozin on an FDA-published shortage or outsourcing list, which further constrains bulk compounding pathways.

The HealthRX clinical team uses the following decision framework to help Mississippi providers think through the access pathway for dapagliflozin:

HealthRX Dapagliflozin Access Decision Framework (Mississippi, 2026)

1. Commercial insurance present? Use the AstraZeneca $0 savings card first. Confirm annual max with the pharmacy at fill.
2. Mississippi Medicaid only? File a PA with supporting documentation citing ADA 2024 Standards and DAPA-HF data. Simultaneously explore AZ&ME program enrollment.
3. Uninsured with income at or below 600% FPL? Apply directly to AZ&ME. Allow two to four weeks for enrollment.
4. Uninsured, income above 600% FPL, or PA denied? Evaluate 503A compounded dapagliflozin with full documentation of clinical rationale beyond cost alone.
5. No 503A option viable? Consider alternative SGLT2 inhibitors (empagliflozin, canagliflozin) with current GoodRx pricing and formulary status before switching drug class.

Why the Price Matters: Dapagliflozin's Clinical Evidence Base

The cost conversation becomes more urgent when you review what dapagliflozin actually does in controlled trials. In DAPA-HF (N=4,744, published NEJM 2019), dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [5] That result was consistent regardless of whether patients had type 2 diabetes at baseline.

DECLARE-TIMI 58 (N=17,160) studied dapagliflozin in patients with type 2 diabetes at cardiovascular risk and demonstrated a 17% relative reduction in hospitalization for heart failure (HR 0.83; 95% CI 0.73 to 0.95). [6] The trial ran for a median of 4.2 years.

The DAPA-CKD trial (N=4,304) reported a 39% relative risk reduction in the composite of sustained decline in eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001). [7] The benefit was present in patients with and without type 2 diabetes.

Dr. John McMurray, lead investigator of DAPA-HF, stated: "Dapagliflozin reduced the risk of worsening heart failure or death from cardiovascular causes, and the magnitude of the benefit was similar in patients with and without diabetes." [5]

Mississippi's cardiovascular disease mortality rate is among the highest in the United States. According to the CDC, Mississippi's age-adjusted heart disease death rate was 267.5 per 100,000 population in 2021, compared with the national average of 173.8. [8] For a state with this burden of disease, access barriers to evidence-based cardioprotective medications carry measurable population-level consequences.

Telehealth Prescribing of Farxiga in Mississippi

Telehealth prescribing of Farxiga is permitted in Mississippi. The state does not restrict SGLT2 inhibitor prescribing to in-person visits. Mississippi follows federal telehealth rules for controlled substances, and dapagliflozin is not a controlled substance, so no additional prescribing restrictions apply beyond standard licensing requirements.

Prescribers using telemedicine platforms must hold a valid Mississippi medical license or comply with the Mississippi State Board of Medical Licensure's telemedicine provisions, which allow out-of-state licensed physicians to practice telemedicine in Mississippi under certain registration pathways. A telehealth visit can generate a valid dapagliflozin prescription that can be filled at any Mississippi retail pharmacy or sent electronically to a 503A compounding pharmacy.

HealthRX clinicians licensed in Mississippi conduct synchronous video visits for cardiovascular risk reduction, type 2 diabetes management, and CKD, and can prescribe dapagliflozin, coordinate savings card enrollment, and submit PA documentation to Mississippi Medicaid or MCO plans where indicated.

How Farxiga Compares to Other SGLT2 Inhibitors on Cost in Mississippi

Dapagliflozin (Farxiga) is not the only SGLT2 inhibitor on the market. Empagliflozin (Jardiance) and canagliflozin (Invokana) are alternatives with overlapping indications. Their cash prices in Mississippi are broadly similar to Farxiga, ranging from $580 to $640 per month retail in 2026. Ertugliflozin (Steglatro) is generally slightly less expensive at approximately $440 per month cash.

Mississippi Medicaid's PDL coverage for other SGLT2 inhibitors should be verified directly with the DOM or the MCO, as formulary decisions can change between annual review cycles. As of mid-2025, no SGLT2 inhibitor sits comfortably on the Mississippi DOM open formulary without prior authorization.

Generic empagliflozin received FDA tentative approval in 2024 but has not yet entered commercial distribution in the United States due to ongoing patent litigation. If generics reach the market during 2025 or 2026, prices could drop substantially, potentially to the $50 to $100 per-month range based on generic pricing patterns observed with other recently genericized branded medications.

The ADA 2024 Standards note that within the SGLT2 inhibitor class, drug selection should consider the specific cardiovascular or renal indication, as trial populations differed across agents. [3] For heart failure with reduced ejection fraction specifically, dapagliflozin has the most strong randomized trial evidence to date, making generic substitution a clinical conversation rather than a simple formulary swap.

Practical Steps for Mississippi Patients Starting Dapagliflozin in 2026

Getting dapagliflozin started in Mississippi in 2026 involves a short, concrete checklist. First, confirm your insurance type: commercial, Medicaid, Medicare, or uninsured. That single answer determines which of the cost pathways above applies.

Second, if commercially insured, call your plan's pharmacy benefits number and ask whether dapagliflozin 10 mg (Farxiga) is on your formulary and at what tier. Tier placement drives your actual copay. Then enroll in the AstraZeneca savings card before your first fill.

Third, if you are on Mississippi Medicaid, ask your prescriber to submit a PA and simultaneously apply to AZ&ME. The two processes can run in parallel. PA approval may take three to fourteen business days; AZ&ME enrollment typically takes two to four weeks.

Fourth, if you are uninsured and above the AZ&ME income threshold, or if you prefer a lower monthly cost and have a clinical rationale your prescriber can document, ask specifically about 503A compounded dapagliflozin. Confirm the pharmacy holds a current Mississippi Board of Pharmacy license before filling.

Fifth, a baseline set of labs is appropriate before starting: serum creatinine, eGFR, serum potassium, and a urinalysis. Dapagliflozin is not recommended for patients with an eGFR below 25 mL/min/1.73 m2 for glycemic indications, though the CKD and heart failure indications allow initiation at lower eGFR thresholds per the FDA label. [2]

Patients with recurrent urinary tract infections, a history of diabetic ketoacidosis, or active genitourinary symptoms should discuss those histories with their prescriber before starting. The prescriber conducting your telehealth visit will review contraindications during the visit.